Cargando…
Biosimilars; a unique opportunity for Iran national health sector and national pharmaceutical industry
Autor principal: | Cheraghali, Abdol Majid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3555876/ https://www.ncbi.nlm.nih.gov/pubmed/23351613 http://dx.doi.org/10.1186/2008-2231-20-35 |
Ejemplares similares
-
Trends in Iran Pharmaceutical Market
por: Cheraghali, Abdol Majid
Publicado: (2017) -
Policies and measures implemented to reduce the impact of international sanctions on Iran's pharmaceutical sector
por: Emami, Farideh, et al.
Publicado: (2022) -
Implications of Confidential Unit Exclusion in Providing Sufficient Safe Blood for the National Health System
por: Cheraghali, Abdol Majid
Publicado: (2011) -
Cost effectiveness of Iran national plasma contract fractionation program
por: Cheraghali, Abdol Majid
Publicado: (2012) -
Impacts of international sanctions on Iranian pharmaceutical market
por: Cheraghali, Abdol Majid
Publicado: (2013)